We're the national organization providing support, resources, volunteer opportunities and hope for people fighting pancreatic ...
The Carol Kulok Award for Compassion is given to a PanCAN Patient Services team member who has gone above and beyond services ...
Join PanCAN on World Pancreatic Cancer Day, November 20, at 11 a.m. PT / 2 p.m. ET, for a free webinar featuring top ...
PanCAN welcomes Jon Mahrt, Chief Executive Officer of Optum Rx and Chief Growth Officer of Optum to the Board of Directors. In this Q&A, Jon shares his personal connection to the cause, his passion ...
A new PanCAN-authored paper uses feedback provided by patients with pancreatic cancer to identify trends in reporting pain. Among the key findings: Pain is more likely to be reported by pancreatic ...
Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights into the latest news and ...
Editor’s note: In this heartfelt interview, Jaylen Baron shares the story of her mother, Jane – an inspiring dance teacher, mentor and fighter – whose legacy is honored every year at PanCAN ...
Editor’s Note: PanCAN volunteers devote their time, energy and passion year-round to improving the lives of everyone impacted by pancreatic cancer. To celebrate Volunteer Appreciation Week 2025 (April ...
Looking for a fresh, nutrient-packed meal? This Bright & Fresh Citrus Strawberry Salad is packed with vitamins, antioxidants, and lean protein—supporting overall health and helping to reduce the risk ...
Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights into the latest news and ...
Pancreatic Cancer Action Network Calls for Urgently Needed Research and Funding for Effective Early Detection Strategy and New Treatments for Patients LOS ANGELES, Calif. – (January 16, 2025) – After ...
The U.S. Food and Drug Administration has granted accelerated approval for a new drug targeting a tumor alteration called NRG1 gene fusion found in roughly 3% of patients with pancreatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback